The DOI matches its Crossref record.
Development of Phage Lysins as Novel Therapeutics: A Historical Perspective
Open accessAbstract
Bacteriophage lysins and related bacteriolytic enzymes are now considered among the top antibiotic alternatives for solving the mounting resistance problem. Over the past 17 years, lysins have been widely developed against Gram-positive and recently Gram-negative pathogens, and successfully tested in a variety of animal models to demonstrate their efficacy. A lysin (CF-301) directed to methicillin resistant Staphylococcus aureus (MRSA) has effectively completed phase 1 human clinical trials, showing safety in this novel therapeutic class. To validate efficacy, CF-301 is currently the first lysin to enter phase 2 human trials to treat hospitalized patients with MRSA bacteremia or endocarditis. If successful, it could be the defining moment leading to the acceptance of lysins as an alternative to small molecule antibiotics. This article is a detailed account of events leading to the first therapeutic use and ultimate development of phage-encoded lysins as novel anti-infectives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
The global preclinical antibacterial pipeline
Theuretzbacher, U., Outterson, K., Engel, A., & Karlén, A. (2020) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0288-0 · Cited by 738
The role of vaccines in combatting antimicrobial resistance
Micoli, F., Bagnoli, F., Rappuoli, R., & Serruto, D. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-00506-3 · Cited by 500
The Advantages and Challenges of Using Endolysins in a Clinical Setting
Murray, E., Draper, L. A., Ross, R. P., & Hill, C. (2021) · Viruses · doi:10.3390/v13040680 · Cited by 263
The applications of animal models in phage therapy: An update
Mehmood Khan, F., Manohar, P., Singh Gondil, V., Mehra, N., Kayode Oyejobi, G., Odiwuor, N., Ahmad, T., & Huang, G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2175519 · Cited by 32
Metadata
- Authors
- Fischetti, V. A.
- Venue
- Viruses
- Publisher
- MDPI AG
- Published
- 2018-06-07
- Volume
- 10
- Issue
- 6
- Pages
- 310
- ISSN
- 1999-4915 (ISSN-L)
- OpenAlex
- W2805963788
- Cited by
- 185
- References
- 0
- FWCI
- 14.85
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. https://app.cochat.ai/papers/10.3390/v10060310
- The paper
- Fischetti, V. A. (2018). Development of Phage Lysins as Novel Therapeutics: A Historical Perspective. Viruses. https://doi.org/10.3390/v10060310
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.